|
|
Training Program in Cancer Biology
|
5T32CA078207-19
|
$554,252
|
|
AARONSON, STUART
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Preclinical analyses of advanced prostate cancer in genetically-engineered mice
|
2R01CA173481-06
|
$385,883
|
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
A biomarker-driven strategy to guide the use of radiotherapy in non-small cell lung cancer
|
1R37CA222294-01A1
|
$366,000
|
|
ABAZEED, MOHAMED
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
|
Novel platform linking cancer-specific glycosylation with cell signaling outcomes
|
1R21CA229044-01
|
$225,250
|
|
ABBOTT, KAREN
|
UNIV OF ARKANSAS FOR MED SCIS
|
|
|
Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance
|
5R01CA201247-03
|
$511,614
|
|
ABDEL-WAHAB, OMAR
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Gastric and Esophageal Malignancies in Northern Iran (GEMINI): Case-Control Study
|
ZIA CP000185 - 10318
|
$9,297
|
$9,297
|
Abnet, Christian
|
DCEG (NCI)
|
|
|
The Golestan Cohort Study
|
ZIA CP000185 - 10361
|
$32,990
|
$32,990
|
Abnet, Christian
|
DCEG (NCI)
|
|
|
Master Regulatory MicroRNAs in Glioblastoma
|
5U01CA220841-02
|
$452,813
|
|
ABOUNADER, ROGER
|
UNIVERSITY OF VIRGINIA
|
|
|
Randomized Placebo-Controlled Trial of a Gastrin Receptor Antagonist in Barretts
|
1R03CA186218-01A1
|
$81,186
|
$81,186
|
ABRAMS, JULIAN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-10
|
$461,172
|
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-04
|
$2,184,301
|
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
|
Nanoparticle mediated microenvironmental targeting of CCL3 signaling for the treatment of acute myelogenous leukemia
|
1F31CA228391-01
|
$42,418
|
|
ACKUN-FARMMER, MARIAN
|
UNIVERSITY OF ROCHESTER
|
|
|
Discovery and Characterization of Mutations in Breast and Ovarian Cancers
|
5R50CA211280-03
|
$215,047
|
|
ADAMSON, AARON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
AFRICAN FEMALE BREAST CANCER EPIDERMIOLOGY (AFBRECANE) STUDY
|
5U01HG009784-02
|
$85,000
|
|
ADEBAMOWO, CLEMENT
|
INSTITUTE OF HUMAN VIROLOGY
|
|
|
Genetic identification of novel mTORC1 regulators and homeostatic signaling mechanisms
|
1F31CA228241-01
|
$44,524
|
|
ADELMANN, CHARLES
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
|
University of North Carolina Womens Interagency HIV Study UNC WIHS
|
3U01AI103390-05S1
|
$60,652
|
|
ADIMORA, ADAORA
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
Probing the role of the IRE1alpha-XBP1 pathway in normal and malignant hematopoiesis
|
5K22CA218467-02
|
$192,575
|
|
ADORO, STANLEY
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities ( 1 of 3)
|
5U54CA163069-05
|
$870,850
|
$17,417
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-08
|
$1,347,488
|
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
|
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
|
1R01CA236615-01
|
$392,764
|
|
ADUSUMILLI, PRASAD
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Developing targeted activatable peptides to amplify radiosensitizer delivery
|
5R03CA219744-02
|
$77,500
|
|
ADVANI, SUNIL
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
5R03CA212798-02
|
$74,250
|
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
5R03CA219336-02
|
$74,250
|
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
|
Genetics of Graft-versus-Host Disease
|
1R01CA231141-01
|
$265,229
|
|
AFSHAR-KHARGHAN, VAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
New Roles for the WTX Tumor Suppressor and Endocytosis in WNT signaling
|
1F31CA228289-01
|
$34,190
|
|
AGAJANIAN, MEGAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
3R01CA195708-05S1
|
$94,087
|
$94,087
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
|
Colon Cancer Chemoprevention by Flavonoid Silibinin
|
5R01CA112304-10
|
$286,515
|
$286,515
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
5R01CA195708-02
|
$387,195
|
$387,195
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
5R01CA195708-05
|
$382,616
|
$382,616
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-02
|
$737,200
|
$110,580
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
SPARC as a regulator of collagen signaling in Pancreatic Cancer
|
5F31CA168350-03
|
$30,485
|
$30,485
|
AGUILERA, KRISTINA
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
|
5K08CA218420-02
|
$177,120
|
$177,120
|
AGUIRRE, ANDREW
|
DANA-FARBER CANCER INST
|
|
|
(PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
|
5R01CA180149-03
|
$577,096
|
$577,096
|
AGUS, DAVID
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
Studying Colonic Stem-Cell Niche Using Microengineered Gradient-Generating Device
|
5F31CA183309-02
|
$33,265
|
$33,265
|
AHMAD, ASAD
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
APC Tumor Suppressor in Cell Differentiation and Death
|
5R01CA105038-10
|
$262,280
|
$262,280
|
AHMED, YASMATH
|
DARTMOUTH COLLEGE
|
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
$315,284
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Mutagenesis and migration in glioblastoma cells
|
1R21CA220111-01A1
|
$179,240
|
|
AHN, EUN HYUN
|
UNIVERSITY OF WASHINGTON
|
|
|
Prospective Study of Human Oral Microbiome and Pancreatic Cancer Risk
|
5R01CA164964-02
|
$593,181
|
$593,181
|
AHN, JIYOUNG
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
|
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer
|
5R01CA185357-02
|
$490,967
|
$490,967
|
AHUJA, NITA
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Elucidating the role and regulation of epithelial plasticity in metastasis
|
5F31CA177163-02
|
$29,766
|
$29,766
|
AIELLO, NICOLE
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junction
|
5R01CA172741-03
|
$279,793
|
$279,793
|
AJANI, JAFFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
Dr. Keiko Akagi, A Bioinformatics Specialist in Cancer Genomics Research at OSU Comprehensive Cancer Center
|
5R50CA211533-03
|
$122,475
|
|
AKAGI, KEIKO
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
Integrated analysis of protein expression data from the Reverse Phase Protein Array (RPPA) platform
|
5U24CA210950-03
|
$279,908
|
|
AKBANI, REHAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
MULTIMODAL PRECLINICAL CANCER IMAGING AND THERAPY RESEARCH SPECIALIST
|
5R50CA211481-04
|
$170,003
|
|
AKERS, WALTER
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
|
Metabolic Syndrome and Epigenetic Markers of Breast Cancer in Nigerian Women
|
5K01TW010271-03
|
$134,531
|
|
AKINYEMIJU, TOMI
|
UNIVERSITY OF KENTUCKY
|
|
|
Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade
|
1R43CA228721-01
|
$299,607
|
|
AKPORIAYE, EMMANUEL
|
VEANA THERAPEUTICS, LLC
|
|
|
ATBC Study
|
ZIA CP010195 - 03031
|
$871,993
|
$130,799
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
|
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers
|
1P01CA217805-01A1
|
$2,105,511
|
|
ALBELDA, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
3P30CA138313-07S1
|
$34,031
|
$2,382
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Total relevant funding to Digestive Diseases for this search: $637,715,335
|
